尔康制药发预亏，预计2025年度归母净亏损3.25亿元至3.85亿元

Group 1 - The company Erkang Pharmaceutical (300267.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of between 325 million yuan and 385 million yuan [1] - The net loss after deducting non-recurring gains and losses is projected to be between 332 million yuan and 392 million yuan [1]